Dossier assessment
Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Fostemsavir (HIV-Infektion) - Nutzenbewertung gemäß § 35a SGB V
-
Dossier assessment
Fostemsavir (HIV-Infektion) - Nutzenbewertung gemäß § 35a SGB V
Dossier assessment
Indication:
Adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen
Result of dossier assessment:
Added benefit not proven.
Project details
- Project no.
- A21-33
- Commission
- Commission awarded on 26.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.